RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license ...
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and ...
Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar ...
RAPT Therapeutics is upgraded to a 'Buy' due to promising pipeline progress and attractive valuation after a significant share price decline. Ozureprubart, RAPT's lead candidate, showed favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback